[Special Stock] PCL Leads $70 Trillion Market with US FDA-Approved AI Diagnostic Device... "Expecting Management of Obesity and Diabetes"

PCLE is showing strong performance. The news that its AI-based diagnostic device ‘PCLOK II PREP UNIVERSAL’ received approval from the U.S. Food and Drug Administration (FDA) appears to be influencing its stock price.

As of 9:56 AM on the 30th, PCLE was trading at 4,030 KRW, up 695 KRW (20.84%) compared to the previous trading day.

PCLOK II PREP UNIVERSAL is a fully automated system that can automatically detect and preprocess samples such as blood, urine, saliva, and nasal mucus collected from the human body regardless of sample type through AI, enabling faster and more convenient on-site diagnosis. It is an improved version of the point-of-care testing (POCT) device PCLOK II, with enhanced sensitivity and accuracy.

It is characterized by the ability to diagnose various chronic diseases, cancer, viruses, and infectious diseases all at once on-site. With excellent accuracy and user convenience, it also has potential for future use as a home medical device.

According to U.S. business consulting firm Frost & Sullivan, the in vitro diagnostics market is expected to grow at a compound annual growth rate of 6.9%, from $99.22 billion in 2021 to $138.34 billion in 2026. By technology, clinical immunoassays (approximately $35.9 billion), molecular diagnostics (approximately $30.4 billion), and POCT (approximately $19.6 billion) are projected to lead by 2025.

PCLOK II PREP UNIVERSAL operates on a single platform integrating existing immunoassays and clinical chemistry, conducting immunochemical diagnostics using antigen and antibody reactions.

PCLE evaluated that if chronic diseases manageable at home, such as obesity and diabetes, are added to the test items, the related market size will grow rapidly.

PCLE stated, "We plan to participate in ‘CES 2024,’ the world’s largest electronics exhibition held in January next year, based on PCLOK II PREP UNIVERSAL and PCLOK II," and explained, "We will accelerate our entry into the U.S. market as a specialized in vitro diagnostics company."

The global private alternative investment group GEM has made an additional investment of 30 billion KRW following the acquisition of 4 million existing shares of PCLE. PCLE announced on the 23rd that it will conduct a third-party allotment capital increase worth 30 billion KRW. The third-party allotment recipient is GEM Global Yield LLC SCS (hereinafter GEM), a global private alternative investment group. GEM is a New York-based alternative investment management firm with $3.4 billion (approximately 4.5 trillion KRW) under management, focusing on emerging markets worldwide through various investment vehicles. GEM has completed over 570 transactions in more than 70 countries.